comparemela.com

Latest Breaking News On - Andreas kj - Page 2 : comparemela.com

Positive interim data from phase lla trial of FG001 in head & neck cancer presented as a case report at the World Molecular Imaging Congress in Prague

FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to see the first data from FG001 study guiding cancer surgery in patients with head & neck cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague. The presentation contains a patient case. The poster “Optical-Guided Surgery in Patients .

Prague
Praha
Hlavníesto
Czech-republic
Denmark
Copenhagen
Køavn
Fluoguideas-fluoguide
Andreas-kj
Anders-christensen
World-molecular-imaging-congress
Guided-surgery

Curasight to present at HC Andersen Capital and Økonomisk Ugebrev

Copenhagen, Denmark, 26 May 2023 - Curasight A/S hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company s Interim Report Q1 2023 at HC. | May 26, 2023

Copenhagen
Køavn
Denmark
Ulrich-krasilnikoff
Curasightas-curasight
Andreas-kj
Life-science-investor-conference
Positron-emissions-tomography
Curasightas-stock-exchange
News
Information

Curasight: Interim report Q1 2023

Curasight: Interim report Q1 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Copenhagen
Køavn
Denmark
Ulrich-krasilnikoff
Andreas-kj
Curasightas-curasight
Curium-inc
Redeye-fight-cancer-seminar
Annual-report
Annual-general

Curasight: Interim report Q1 2023 | MarketScreener

COPENHAGEN, Denmark, May 25, 2023 /PRNewswire/  Curasight A/S hereby publishes the interim report Q1 2023. The interim report is available as an attached file to this release and on the. | May 25, 2023

Copenhagen
Køavn
Denmark
Ulrich-krasilnikoff
Andreas-kj
Curasightas-curasight
Curium-inc
Redeye-fight-cancer-seminar
Annual-report
Annual-general
Curasightas-stock-exchange
News

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.